Overview

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.
Phase:
Phase 1
Details
Lead Sponsor:
Telsar Pharma Inc.